Plant-derived compound shows promise against arthritis inflammation

A compound extracted from medicinal bark eased joint swelling and reduced tissue damage in rats with arthritis-like inflammation, a new study has found. The results suggest a possible connection between the body’s fat-processing pathways and the immune response that damages joints.

Rheumatoid arthritis develops when the immune system mistakenly targets the joint lining. The condition can lead to persistent pain, swelling and damage to cartilage and bone, which is why researchers continue to look for better ways to control inflammation.

The substance, known as obakulactone, is derived from Phellodendri cortex, a bark used in traditional medicine. In the study, researchers tested it in rats given a compound that triggers inflammation resembling some aspects of rheumatoid arthritis.

Animals were given different doses of obakulactone each day for 21 days. Compared with untreated rats, those that received the compound showed less joint swelling and improved cartilage and joint-lining condition.

The researchers also examined immune activity and found lower levels of several inflammation-related signals, including IL-6 and TNF-alpha. These proteins help immune cells communicate, but when produced in excess they can intensify inflammation.

They also reported changes in macrophages, immune cells that can either drive inflammation or help calm it. Treatment appeared to push these cells toward a less inflammatory state and reduced the number of other immune cells associated with joint damage.

To understand how the compound worked, the team looked at its effect on ACOT1, a protein involved in fatty acid metabolism. The findings indicated that obakulactone promoted the breakdown of ACOT1, helping restore the balance of certain fats inside cells.

That result points to fat metabolism as another possible target in rheumatoid arthritis research, alongside the immune pathways already under investigation.

The experiments were done in rats rather than humans, however. The animal model captures only part of what happens in human rheumatoid arthritis, and the doses used in the study are not established treatments for patients.

Researchers still need to determine whether obakulactone is safe in people, how it is processed by the body and whether it can provide benefits beyond current medicines.

The study, published in Engineering, offers an early biological lead rather than proof that the plant compound can treat rheumatoid arthritis in patients.

Blood tests also showed changes in markers linked to rheumatoid arthritis, with stronger effects seen at higher doses. Those lab results support the proposed anti-inflammatory action, but they do not show whether a human patient would have less pain or better movement.

The study appeared in Engineering.

If you are interested in this topic, please read articles about How turmeric can help seniors fight inflammation, and Turmeric: nature’s golden answer to inflammation.

For more information, please see articles about Why turmeric is a health game-changer, and How turmeric can help fight inflammation.

Source: Higher Education Press.